High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Growth: Awesome revenue growth! Revenue grew 41.2% over last year and 59.9% in last three years on TTM basis.
Size: Market Cap wise it is among the top 20% companies of india.
Momentum: Stock price has a strong positive momentum. Stock is up 15.1% in last 30 days.
Balance Sheet: Strong Balance Sheet.
Smart Money: Smart money has been increasing their position in the stock.
Past Returns: Outperforming stock! In past three years, the stock has provided 17.2% return compared to 9.1% by NIFTY 50.
Profitability: Very strong Profitability. One year profit margin are 20%.
No major cons observed.
Valuation | |
|---|---|
| Market Cap | 36.51 kCr |
| Price/Earnings (Trailing) | 54.66 |
| Price/Sales (Trailing) | 10.81 |
| EV/EBITDA | 33.08 |
| Price/Free Cashflow | 89.45 |
| MarketCap/EBT | 41.82 |
| Enterprise Value | 37.72 kCr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 3.38 kCr |
| Rev. Growth (Yr) | 34% |
| Earnings (TTM) | 663.55 Cr |
| Earnings Growth (Yr) | 123.9% |
Profitability | |
|---|---|
| Operating Margin | 26% |
| EBT Margin | 26% |
| Return on Equity | 16.69% |
| Return on Assets | 10.4% |
| Free Cashflow Yield | 1.12% |
Growth & Returns | |
|---|---|
| Price Change 1W | 7.6% |
| Price Change 1M | 15.1% |
| Price Change 6M | 27.6% |
| Price Change 1Y | 73.3% |
| 3Y Cumulative Return | 17.2% |
| 5Y Cumulative Return | 18.2% |
| 7Y Cumulative Return | 39% |
| 10Y Cumulative Return | 33.4% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -1.23 kCr |
| Cash Flow from Operations (TTM) | 893.57 Cr |
| Cash Flow from Financing (TTM) | 344.21 Cr |
| Cash & Equivalents | 22.55 Cr |
| Free Cash Flow (TTM) | 408.23 Cr |
| Free Cash Flow/Share (TTM) | 79.66 |
Balance Sheet | |
|---|---|
| Total Assets | 6.38 kCr |
| Total Liabilities | 2.4 kCr |
| Shareholder Equity | 3.97 kCr |
| Current Assets | 2.79 kCr |
| Current Liabilities | 1.07 kCr |
| Net PPE | 3.18 kCr |
| Inventory | 445.56 Cr |
| Goodwill | 87.76 Cr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.19 |
| Debt/Equity | 0.31 |
| Interest Coverage | 6.41 |
| Interest/Cashflow Ops | 8.58 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 13.5 |
| Dividend Yield | 0.19% |
| Shares Dilution (1Y) | 3.3% |
| Shares Dilution (3Y) | 3.4% |
Growth: Awesome revenue growth! Revenue grew 41.2% over last year and 59.9% in last three years on TTM basis.
Size: Market Cap wise it is among the top 20% companies of india.
Momentum: Stock price has a strong positive momentum. Stock is up 15.1% in last 30 days.
Balance Sheet: Strong Balance Sheet.
Smart Money: Smart money has been increasing their position in the stock.
Past Returns: Outperforming stock! In past three years, the stock has provided 17.2% return compared to 9.1% by NIFTY 50.
Profitability: Very strong Profitability. One year profit margin are 20%.
No major cons observed.
Investor Care | |
|---|---|
| Dividend Yield | 0.19% |
| Dividend/Share (TTM) | 13.5 |
| Shares Dilution (1Y) | 3.3% |
| Earnings/Share (TTM) | 130.36 |
Financial Health | |
|---|---|
| Current Ratio | 2.61 |
| Debt/Equity | 0.31 |
Technical Indicators | |
|---|---|
| RSI (14d) | 68.91 |
| RSI (5d) | 95.02 |
| RSI (21d) | 80.32 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Sell |
| RSI21 Signal | Sell |
| SMA 5 Signal | Buy |
| SMA 10 Signal | Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Buy |
| SMA 100 Signal | Buy |
Summary of Navin Fluorine International's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Navin Fluorine International Limited's management provided an optimistic outlook for the upcoming financial year, indicating strong growth momentum driven by recent project commissions and expansions. The company achieved a revenue growth of 34% year-on-year in Q4 FY26, with consolidated revenue reaching INR 938 crores. For the full year FY26, net operating revenues grew to INR 3,314 crores, reflecting a 41% increase supported by robust performance across its specialty chemicals, CDMO, and HPP segments.
Significant forward-looking points include:
Capacity Expansion: Management highlighted the commissioning of additional HFC capacities of 32 MPP and the Chemours project, both expected to transition to revenue generation during FY27.
Continued Growth in CDMO: The CDMO business showed a remarkable growth of 61% year-on-year in Q4, reaching INR 186 crores, with ongoing work on approximately 55 molecules, half of which are in late-stage development.
Innovative Development: Management confirmed that the diversification across products and geographies is aligned with its long-term growth strategy, aiming for a balanced approach between product and service offerings.
Improved Margins: Operating EBITDA for FY26 doubled to INR 1,082 crores, with margins expected to be around 30% for FY27, demonstrating strong operating leverage and effective cost management.
Healthy Financial Position: The company's balance sheet remains strong, with a net debt to equity ratio of 0.01x and improved working capital days to 74 days from 90 days, signifying operational efficiency.
Dividend Declaration: A final dividend of INR 8.6 per share was declared, which signifies management's commitment to returning value to shareholders amidst growth.
Overall, the management's comments project confidence in capturing long-term growth opportunities while navigating through market uncertainties.
1. Question: "Can you provide details on the raw material availability situation in the Middle East, particularly regarding sulfur and methanol?"
Answer: The raw material situation remains volatile, but we've not yet experienced disruption. Our vigilant management has allowed us to navigate price inflation by passing costs to customers. As for inventory, we maintain healthy stock levels and haven't shut down operations. Customer demand remains robust, and while there might be pent-up restocking demand, we do not anticipate demand destruction at this stage.
2. Question: "What is our visibility regarding CDMO late-stage contracts, and how many are we currently working on?"
Answer: We are actively working on approximately 55 molecules in total, with about half in late-stage commercial development. The therapeutic areas include oncology, neurology, and cardiovascular health. We have confidence that these will translate into revenues, contributing to our target of reaching $100 million in CDMO revenue by FY27.
3. Question: "Regarding the Chemours project, by when can we expect visibility on potential capital expenditure?"
Answer: The Chemours project is slated for commissioning at the end of June or early July. As we assess the market size over the following 18 months, we will determine the capex required to further support growth. The unique nature of the product and the AI market's demands position us well for future investment.
4. Question: "Will there be price adjustments related to the raw material inflation, especially for contracts like HFO and CDMO?"
Answer: Pricing mechanisms vary across our contracts. We aim to accelerate recovery in costs, and we have mechanisms to pass through increases. While there may be a lag in adjustments, we have open communication with our customers regarding price hikes due to inflation.
5. Question: "What are our expectations for growth in the Specialty Chemicals and HPP segments for FY27?"
Answer: We are optimistic about double-digit growth in both segments, driven by ongoing projects and operational efficiencies. The commissioning of our HF plant and the full ramp-up of the Nectar project should bolster revenues significantly as we target higher capacity utilization moving forward.
Understand Navin Fluorine International ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| MAFATLAL IMPEX PRIVATE LIMITED (Mafatlal Exim Pvt Ltd amalgamated with Mafatlal Impex Pvt Ltd) | 25.44% |
| QUALIFIED INSTITUTIONAL BUYER | 8% |
| LIFE INSURANCE CORPORATION OF INDIA | 5.2% |
| GOVERNMENT PENSION FUND GLOBAL | 3.92% |
| SBI MUTUAL FUNDS | 3.8% |
| AXIS MUTUAL FUND TRUSTEE LIMITED | 2.33% |
| ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED | 1.29% |
| NIPPON LIFE INDIA TRUSTEE LTD | 1.28% |
| BARODA BNP PARIBAS ELSS FUND | 1.13% |
| EDELWEISS MUTUAL FUNDS | 1.09% |
| GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY | 1.06% |
| AJAY UPADHYAYA | 1.01% |
| VISHAD MAFATLAL AS TRUSTEE OF VISHAD P MAFATLAL FAMILY TRUST NO. 1 | 0.75% |
| VISHAD PADMANABH MAFATLAL | 0.64% |
| VISHAD PADMANABH MAFATLAL PUBLIC CHARITABLE TRUST NO. 1 | 0.24% |
| PADMANABH ARVIND MAFATLAL (HUF) | 0.03% |
| VISHAD P. MAFATLAL PAM HUF1 P MAFATLAL | 0.01% |
| PAMIL INVESTMENTS PVT LTD | 0.01% |
| TEREBINTH VENTURES PRIVATE LIMITED (formerly known as Anshi Ventures Private Limited) | 0% |
| RUPAL VISHAD MAFATLAL | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
Detailed comparison of Navin Fluorine International against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| PIDILITIND | Pidilite Industries | 1.51 LCr | 14.87 kCr | +6.50% | -1.70% | 61.72 | 10.17 | - | - |
| SRF | SRF | 80.6 kCr | 15.89 kCr | +9.00% | -6.20% | 43.92 | 5.07 | - | - |
| FLUOROCHEM | Gujarat Fluorochemicals | 42.08 kCr | 4.91 kCr | +13.20% | -4.80% | 64.12 | 8.56 | - | - |
| AARTIIND | Aarti Industries | 17.49 kCr | 8.31 kCr | +2.00% | +2.80% | 41.73 | 2.11 | - | - |
| GALAXYSURF | Galaxy Surfactants | 6.53 kCr | 5.27 kCr | +4.40% | -16.50% | 24.43 | 1.24 | - | - |
Comprehensive comparison against sector averages
NAVINFLUOR metrics compared to Chemicals
| Category | NAVINFLUOR | Chemicals |
|---|---|---|
| PE | 54.66 | 44.62 |
| PS | 10.81 | 4.21 |
| Growth | 41.2 % | 7.4 % |
Navin Fluorine International Limited manufactures and sells specialty fluorochemicals in India and internationally. The company offers refrigerants for various applications, including window and split room air conditioners, chillers, packaged air conditioners, commercial and industrial refrigeration units, intermediate for active pharmaceutical ingredient, fluoropolymer resins, domestic and industrial refrigerators, and mobile air conditioning under the Mafron brand for original equipment manufacturer, service technicians, and equipment owners. It provides inorganic fluoride products, such as ammonium bifluoride, potassium fluoride, sodium fluoride, potassium fluorotitanate, potassium fluoroborate, hexafluorophosphoric acid, and hydrofluo pyridine and hydrofluo urea complex products for oil and gas, stainless steel, pharmaceutical and agrochemicals, abrasives, electronics, and solar energy industries. In addition, the company offers various specialty fluoro intermediates consisting of boron trifluoride gas and adducts for pharmaceutical industry, as well as crop protection, hydrocarbon, and fragrance applications; and contract development and contract manufacturing services comprising basic research, library syntheses, process development, scale up, and batch manufacturing for custom chemical syntheses of fluorinated compounds in the pharmaceuticals, agro chemicals, and specialty chemicals industries. Navin Fluorine International Limited was founded in 1967 and is headquartered in Mumbai, India.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
NAVINFLUOR vs Chemicals (2021 - 2026)